Orion OYJ (OTCMKTS:ORINY) Trading Up 0% - Still a Buy?

Key Points

• Orion OYJ's stock traded flat at $39.85, with a significant decrease in trading volume, down 55% from the average.
• The company reported a net margin of 22.61% and earnings per share (EPS) of $0.33 for the previous quarter, with forecasts estimating an EPS of 1.18 for the current year.
• Orion OYJ focuses on pharmaceutical development for both human and veterinary medicines, offering a range of products including treatments for cancer, pain, and Parkinson's disease.

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) were up 0% during trading on Tuesday . The stock traded as high as $39.85 and last traded at $39.85. Approximately 253 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 565 shares. The stock had previously closed at $39.84.

Orion OYJ Stock Performance

The firm's 50-day moving average is $38.54 and its 200 day moving average is $32.81. The stock has a market cap of $11.25 billion, a PE ratio of 27.11 and a beta of 0.10. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.05 and a current ratio of 1.86.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. The firm had revenue of $472.57 million during the quarter. As a group, research analysts anticipate that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.